Clinical outcomes of marginal ulcer bleeding compared with those of peptic ulcer bleeding.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
05 2023
Historique:
received: 22 08 2022
accepted: 04 01 2023
medline: 5 5 2023
pubmed: 28 1 2023
entrez: 27 1 2023
Statut: ppublish

Résumé

Marginal ulcer bleeding (MUB) is a complication that can occur following several types of surgery. However, few studies exist on it. Therefore, this study aimed to compare the clinical outcomes of MUB with those of peptic ulcer bleeding (PUB). Between January 2013 and December 2017, 5,076 patients underwent emergent esophagogastroduodenoscopy for suspected upper gastrointestinal bleeding. We retrospectively reviewed and analyzed the medical records of MUB and PUB patients and developed a propensity score matching (PSM) method to adjust for between-group differences in baseline characteristics with 1:2 ratios. Sex, age, body mass index (BMI), underlying diseases, and drugs were included as matching factors. A total of 64 and 678 patients were diagnosed with MUB and PUB, respectively, on emergent esophagogastroduodenoscopy, and 62 and 124 patients with MUB and PUB, respectively, were selected after PSM. Rebleeding was significantly higher in patients with MUB than in those with PUB (57.8% vs 9.1%, p < 0.001). Mortality caused by bleeding was higher in patients with MUB than in those with PUB (4.7% vs. 0.4%, p < 0.001). Multivariate analysis revealed that proton pump inhibitor (PPI) administration (odds ratio [OR], 0.14; 95% confidence interval [CI], 0.03-0.56; p = 0.011) after first bleeding was inversely correlated with MUB rebleeding. Large ulcer size (> 1 cm) (OR, 6.69; 95% CI, 1.95-27.94; p = 0.005) and surgery covering pancreas (OR, 3.97; 95% CI, 1.19-15.04) were independent risk factors for MUB rebleeding. MUB showed a severe clinical course than PUB. Therefore, MUB should be managed more cautiously, especially for large ulcers and pancreatic surgery. Prophylactic PPI administration may be helpful in reducing rebleeding in MUB.

Sections du résumé

BACKGROUND
Marginal ulcer bleeding (MUB) is a complication that can occur following several types of surgery. However, few studies exist on it. Therefore, this study aimed to compare the clinical outcomes of MUB with those of peptic ulcer bleeding (PUB).
METHODS
Between January 2013 and December 2017, 5,076 patients underwent emergent esophagogastroduodenoscopy for suspected upper gastrointestinal bleeding. We retrospectively reviewed and analyzed the medical records of MUB and PUB patients and developed a propensity score matching (PSM) method to adjust for between-group differences in baseline characteristics with 1:2 ratios. Sex, age, body mass index (BMI), underlying diseases, and drugs were included as matching factors.
RESULTS
A total of 64 and 678 patients were diagnosed with MUB and PUB, respectively, on emergent esophagogastroduodenoscopy, and 62 and 124 patients with MUB and PUB, respectively, were selected after PSM. Rebleeding was significantly higher in patients with MUB than in those with PUB (57.8% vs 9.1%, p < 0.001). Mortality caused by bleeding was higher in patients with MUB than in those with PUB (4.7% vs. 0.4%, p < 0.001). Multivariate analysis revealed that proton pump inhibitor (PPI) administration (odds ratio [OR], 0.14; 95% confidence interval [CI], 0.03-0.56; p = 0.011) after first bleeding was inversely correlated with MUB rebleeding. Large ulcer size (> 1 cm) (OR, 6.69; 95% CI, 1.95-27.94; p = 0.005) and surgery covering pancreas (OR, 3.97; 95% CI, 1.19-15.04) were independent risk factors for MUB rebleeding.
CONCLUSIONS
MUB showed a severe clinical course than PUB. Therefore, MUB should be managed more cautiously, especially for large ulcers and pancreatic surgery. Prophylactic PPI administration may be helpful in reducing rebleeding in MUB.

Identifiants

pubmed: 36707418
doi: 10.1007/s00464-023-09871-5
pii: 10.1007/s00464-023-09871-5
doi:

Substances chimiques

Proton Pump Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3852-3860

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Shin JS, Chen KW, Lin XZ, Lin CY, Chang TT, Yang CC (1994) Active, bleeding marginal ulcer of Billroth II gastric resection: a clinical experience of 18 patients. Am J Gastroenterol 89:1831–1835
pubmed: 7942677
Luu AM, Vogel SR, Braumann C, Praktiknjo M, Höhn P, Förster S, Janot M, Uhl W, Belyaev O (2021) Risk factors for perforated marginal ulcers following pancreaticoduodenectomy and prospective analysis of marginal ulcer development. Gland Surg 10:739–750
doi: 10.21037/gs-20-763 pubmed: 33708556 pmcid: 7944069
Higa KD, Boone KB, Ho T (2000) Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients–what have we learned? Obes Surg 10:509–513
doi: 10.1381/096089200321593706 pubmed: 11175957
Sacks BC, Mattar SG, Qureshi FG, Eid GM, Collins JL, Barinas-Mitchell EJ, Schauer PR, Ramanathan RC (2006) Incidence of marginal ulcers and the use of absorbable anastomotic sutures in laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2:11–16
doi: 10.1016/j.soard.2005.10.013 pubmed: 16925306
Park Y, Hwang DW, Lee JH, Song KB, Jun E, Lee W, Kwon J, Kim SC (2020) Analysis of symptomatic marginal ulcers in patients who underwent pancreaticoduodenectomy for periampullary tumors. Pancreas 49:208–215
doi: 10.1097/MPA.0000000000001470 pubmed: 32011522
Chung WC, Jeon EJ, Lee KM, Paik CN, Oh YS, Lee YW, Kim SB, Jun KH, Chin HM (2012) Clinical outcomes of the marginal ulcer bleeding after gastrectomy: as compared to the peptic ulcer bleeding with nonoperated stomach. Gastroenterol Res Pract 2012:624327
doi: 10.1155/2012/624327 pubmed: 23304127 pmcid: 3518972
Sapala JA, Wood MH, Sapala MA, Flake TM Jr (1998) Marginal ulcer after gastric bypass: a prospective 3-year study of 173 patients. Obes Surg 8:505–516
doi: 10.1381/096089298765554061 pubmed: 9819081
Schneider BE, Villegas L, Blackburn GL, Mun EC, Critchlow JF, Jones DB (2003) Laparoscopic gastric bypass surgery: outcomes. J Laparoendosc Adv Surg Tech A 13:247–255
doi: 10.1089/109264203322333575 pubmed: 14561253
MacLean LD, Rhode BM, Nohr C, Katz S, McLean AP (1997) Stomal ulcer after gastric bypass. J Am Coll Surg 185:1–7
doi: 10.1016/S1072-7515(01)00873-0 pubmed: 9208953
Sanyal AJ, Sugerman HJ, Kellum JM, Engle KM, Wolfe L (1992) Stomal complications of gastric bypass: incidence and outcome of therapy. Am J Gastroenterol 87:1165–1169
pubmed: 1519574
Gumbs AA, Duffy AJ, Bell RL (2006) Incidence and management of marginal ulceration after laparoscopic Roux-Y gastric bypass. Surg Obes Relat Dis 2:460–463
doi: 10.1016/j.soard.2006.04.233 pubmed: 16925381
Sakran N, Gralnek I, Hamoud M, Dar R (2021) Gastro-colic fistula: a rare complication of a marginal ulcer following one anastomosis gastric bypass. Obes Surg 31:3899–3900
doi: 10.1007/s11695-021-05498-4 pubmed: 34036553
Nam JH, Kim JH, Park JE, Kim HJ, Lee SH, Ahn BK, Chang HK, Park SJ (2005) A case of gastrojejunocolic fistula as a complication after gastrojejunostomy. Clin Endosc 31:116–120
Yamasaki Y, Takenaka R, Hori K, Takemoto K, Kawano S, Kawahara Y, Fujiki S, Okada H (2016) Clinical outcomes of endoscopic hemostasis in marginal ulcer bleeding. Acta Med Okayama 70:469–475
pubmed: 28003672
Leontiadis GI, Sharma VK, Howden CW (2006) Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 1:Cd002094
Csendes A, Burgos AM, Altuve J, Bonacic S (2009) Incidence of marginal ulcer 1 month and 1 to 2 years after gastric bypass: a prospective consecutive endoscopic evaluation of 442 patients with morbid obesity. Obes Surg 19:135–138
doi: 10.1007/s11695-008-9588-6 pubmed: 18581192
Nikolopoulou VN, Thomopoulos KC, Theocharis GI, Arvaniti VA, Vagianos CE (2005) Acute upper gastrointestinal bleeding in operated stomach: outcome of 105 cases. World J Gastroenterol 11:4570–4573
doi: 10.3748/wjg.v11.i29.4570 pubmed: 16052690 pmcid: 4398710
Valenzuela JE, Kogut DG, McCullough AJ, Colón Pagán JR, Shah U, Whipple J, Gilde LR, Simon TJ (1996) Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study. Am J Gastroenterol 91:2516–2522
pubmed: 8946978
Cloud ML, Enas N, Humphries TJ, Bassion S (1998) Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The rabeprazole study group. Dig Dis Sci 43:993–1000
doi: 10.1023/A:1018822532736 pubmed: 9590413
Selby NM, Kubba AK, Hawkey CJ (2000) Acid suppression in peptic ulcer haemorrhage: a ‘meta-analysis.’ Aliment Pharmacol Ther 14:1119–1126
doi: 10.1046/j.1365-2036.2000.00822.x pubmed: 10971227
Liao F, Yang Y, Zhong J, Zhu Z, Pan X, Liao W, Li B, Zhu Y, Chen Y, Shu X (2022) Incidence and risk factors for rebleeding after emergency endoscopic hemostasis for marginal ulcer bleeding. Clin Res Hepatol Gastroenterol 46:101953
doi: 10.1016/j.clinre.2022.101953 pubmed: 35605892
Kim HC, Suzuki T, Kajiwara T, Miyashita T, Imamura M, Tobe T (1987) Exocrine and endocrine stomach after gastrobulbar preserving pancreatoduodenectomy. Ann Surg 206:717–727
doi: 10.1097/00000658-198712000-00006 pubmed: 3689008 pmcid: 1493327
Prosapio JG, Sankar P, Jialal I (2022) Physiology, Gastrin. StatPearls, StatPearls Publishing, Treasure Island (FL)
Sakaguchi T, Nakamura S, Suzuki S, Kojima Y, Tsuchiya Y, Konno H, Nakaoka J, Nishiyama R (2000) Marginal ulceration after pylorus-preserving pancreaticoduodenectomy. J Hepatobiliary Pancreat Surg 7:193–197
doi: 10.1007/s005340050175 pubmed: 10982613

Auteurs

Jun-Young Seo (JY)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Jin Hee Noh (JH)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Ji Yong Ahn (JY)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea. ji110@hanmail.net.

Sang Yong Cho (SY)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Seung-Pyo Oh (SP)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Boram Cha (B)

Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.

Hee Kyong Na (HK)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Jeong Hoon Lee (JH)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Kee Wook Jung (KW)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Do Hoon Kim (DH)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Kee Don Choi (KD)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Ho June Song (HJ)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Gin Hyug Lee (GH)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Hwoon-Yong Jung (HY)

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH